CD&R and McKesson (MCK) confirmed to sign agreement to acquire Option Care Health (OPCH) for USD 32.05/shr or USD 5.80bln enterprise value

Confirmed cash agreements of this kind shift the target's price formation from deal speculation to spread mechanics: the arb consideration becomes the gap between the offer price and the traded level, which prices financing certainty, timeline to close, and antitrust risk rather than fundamentals. Sponsor involvement alongside a strategic buyer is a familiar structure in healthcare services take-privates, and has tended to ease financing questions that pure leveraged bids raise. The relevant antitrust lens here is the overlap between the acquirer's existing distribution and specialty operations and the target's infusion services footprint; vertical combinations in healthcare have drawn longer review cycles than horizontal deals of comparable size, and the regulatory posture toward healthcare consolidation has been the binding constraint in recent episodes. The follow-ons that matter are the definitive agreement terms, the financing disclosure, any break fee, and the initial review posture. For the acquirer, precedent is that large bolt-ons funded with debt reprice the issuer's credit spreads and weigh on the shares near-term pending synergy detail.